Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM103 TILs for the Adjuvant Treatment of NSCLC
NCT07444437Phase 2Recruiting
- Sponsor
- Suzhou BlueHorse Therapeutics
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of LM103 in non-small cell lung cancer (NSCLC), sponsored by Suzhou BlueHorse Therapeutics. Started Feb 2026; status: recruiting.
02
Drugs
LM103
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07444437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444437.